Atezolizumab (anti-PD-L1) (C09-0734-859)

Product introduction:Protein stock solution. Each type of McAb is packed in a frozen storage tube, and its mass is 1MG or 5MG, and its volume is slightly different according to its concentration.Before use, it can be diluted according to its own experimental needs. The solvent is recommended to use deionized sterile water (water for cell culture) or PBS,It is not recommended to use diluents containing antiseptic ingredients for dilution, which will increase cell or animal toxicity.Before dilution, calculate the volume of solvent added. Please refer to the protein concentration on the quality inspection sheet of the purchased batch,For example, the quality inspection document shows that the protein concentration of this batch of monoclonal antibody protein stock solution is 50mg/mlThe volume of protein stock solution corresponding to 5MG package is 5mg (mass)/50mg/ml (concentration)=0.1ML,The protein concentration required for the experiment is 10mg/ml, and the dilution ratio is 50/10=5, so 0.4ML, namely 400ul PBS or sterile deionized water, is required.If the dose is a fixed mass value, such as 0.5MG for a single dose, the corresponding dose volume of protein stock solution is 10ul. It is recommended to increase the dose volume after dilution to reduce the error, because the residual syringe or pipette suction head will affect the experimental effect.Non-reduced CE-SDS:………………………………………….> 90%;SEC-HPLC:………………………………………………………….> 95%;Bacterial Endotoxins Test：…………………………………. .< 10EU/mlResidual Proteins of Host Cell: ……………………………. < 100 ng/mgExogenous residual DNA: …………………………………. . < 100pg/mgResidual Protein A: ……………………………………………. .< 100 ng/mgBiological Activity:………………………………………….……. . 80% to 125% of standardProduct description:A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Specifications and Purity: ~60mg/ml（in buffer）,98%. PubChem CID: 168009942. Isomeric SMILES: CC.CCCC(=NC(CC=C)C1=CC(=C(C=C1)N)S)C=C(C(=O)N(CCC(C)CC)C(C)CC)N.CC=CC(=CC)C(=O)C.